A 32-year-old man from Mumbai presents to the infectious disease clinic with a 6-month history of progressive weight loss (8 kg), chronic diarrhea, and recurrent oral candidiasis. He reports unprotected sexual contact with multiple partners over the past 5 years. On examination, he has generalized lymphadenopathy and oral thrush. His CD4+ count is 180 cells/μL. HIV serology is positive. Which of the following is the most appropriate immediate management regarding antiretroviral therapy (ART) initiation?

Explanation

## Immediate ART Initiation in Advanced HIV Disease **Key Point:** Current WHO and Indian national guidelines recommend immediate ART initiation for all HIV-positive individuals regardless of CD4 count, with particular urgency in those with CD4 < 200 cells/μL. **High-Yield:** The "treat all" strategy (launched globally in 2015, adopted by India in 2017) eliminates the CD4 threshold for ART initiation. This patient has: - CD4 < 200 cells/μL (AIDS-defining) - Active opportunistic infection (oral candidiasis) - Clinical symptoms of advanced disease **Clinical Pearl:** Delaying ART in CD4 < 200 cells/μL significantly increases mortality from opportunistic infections. Immediate ART initiation combined with: - Prophylaxis for PCP (trimethoprim-sulfamethoxazole) at CD4 < 200 - Prophylaxis for MAC (azithromycin) at CD4 < 50 - Antifungal therapy for active candidiasis has reduced AIDS-related deaths by >80% in resource-limited settings. **Mnemonic - ART Timing (IMMEDIATE):** - **I**mmediately for all CD4 < 50 (MAC prophylaxis needed) - **M**ust start within 2 weeks if CD4 < 200 (OI risk) - **M**ay start within 2 weeks if CD4 200–350 - **E**ven if CD4 > 350, start within 3 months - **D**o NOT delay for OI treatment (concurrent management) - **I**nfection prophylaxis overlaps with ART - **A**RT initiation is the most effective OI prevention - **T**iming: earlier = better survival - **E**xception: TB meningitis (delay 2 weeks to reduce IRIS) ## Rationale for Immediate Initiation | Aspect | Immediate ART | Deferred ART | |--------|---------------|-------------| | **Mortality at CD4 < 200** | Reduced by 70–80% | Baseline risk | | **OI incidence** | Reduced by immune reconstitution | High during delay | | **Viral suppression** | Achieved in 8–12 weeks | Ongoing transmission risk | | **Guideline status** | WHO 2019, India 2017 | Obsolete | **Guideline Reference:** India's National AIDS Control Organization (NACO) 2017 guidelines mandate ART initiation for all HIV+ individuals at first visit, regardless of CD4 count or WHO stage [cite:NACO ART Guidelines 2017].